These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19659504)

  • 21. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
    Czendlik CH; Sioufi A; Preiswerk G; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
    Li X; Mo E; Chen L
    Clin Pharmacol Drug Dev; 2022 Jun; 11(6):761-769. PubMed ID: 35289500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjects.
    Jin C; Jeon JY; Im YJ; Jung JA; Kim Y; Park K; Choi Y; Chae SW; Kim MG
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):64-72. PubMed ID: 24290413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
    Tanigawara Y; Yoshihara K; Kuramoto K; Arakawa K
    Drug Metab Pharmacokinet; 2009; 24(4):376-88. PubMed ID: 19745564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
    Chang JS; El-Gamal MI; Lee WS; Anbar HS; Chung HJ; Kim HI; Cho YJ; Lee BS; Lee SA; Moon JY; Lee DJ; Jeon HR; Lee J; Choi YW; Oh CH
    Eur J Med Chem; 2011 Sep; 46(9):3564-9. PubMed ID: 21641692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG; Marbury TC; Robinson TD
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.
    Rosenson RS
    Cardiovasc Drugs Ther; 2009 Aug; 23(4):289-94. PubMed ID: 19641984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
    Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
    Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.
    Rozza F; Trimarco V; Izzo R; Santoro M; Manzi MV; Marino M; Di Renzo G; Trimarco B
    High Blood Press Cardiovasc Prev; 2013 Mar; 20(1):25-32. PubMed ID: 23657962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM; Hilkert R
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics.
    Tanaka H; Nagasawa Y; Matsui I; Hamano T; Iwatani H; Kawada N; Horio M; Ito T; Isaka Y; Imai E
    Clin Exp Nephrol; 2009 Feb; 13(1):61-5. PubMed ID: 18574553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
    Chrysant SG; Dimas B; Shiraz M
    J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects.
    Kim JR; Kim S; Huh W; Ko JW
    Drug Des Devel Ther; 2018; 12():2475-2483. PubMed ID: 30127595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.
    Sengupta P; Nandi U; Pal TK
    Regul Toxicol Pharmacol; 2012 Feb; 62(1):7-15. PubMed ID: 22203042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.